• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not...

cafead

Administrator
Staff member
  • cafead   Jan 13, 2022 at 11:02: AM
via Ahead of its state-of-the-company address at the J.P. Morgan Healthcare Conference, AbbVie took the unusual step of reconfirming its guidance for its blockbusters-in-waiting Rinvoq and Skyrizi, saying it expects the duo's sales to reach a combined $15 billion in 2025.

article source
 

<